Gan Li Pharmaceuticals 2020H1 Performance: Revenue of 1.207 billion yuan Research and development investment of 238 million yuan.

In the first half of 2020, Ganli Pharmaceutical Mendong insulin was approved for listing by the State Drug Administration, the new drug GLR2007 in the United States Phase I clinical trial patients also officially started, 3 main products: insulin glaccerin, insulin and mendon insulin in Europe and the United States key Phase I clinical successfully completed, and the phase III clinical phase of glablin is now in the final stage.
development team and European and American partners Sanders fully cooperate in preparation for the Declaration of Europe and the United States, but also made substantial progress.
in research and development, Gan Li Pharmaceuticals, in addition to continuing to vigorously develop new diabetes-related product pipeline, but also in other areas, such as tumors, immunotherapy, cell therapy drug development is also progressing normally.
investment in research and development in the first half of this year was 238 million yuan, an increase of 18.03 percent.
, the investment in cost-based research and development was RMB187 million, an increase of 105.68 percent, and the share of sales revenue increased from 9.50% in the same period last year to 15.52% in the current period;
In terms of overseas business development, international orders were increased in the first half of the year as countries were affected by the outbreak of the new coronavirus and overseas customers actively stocked up, but overseas shipments were limited and some orders had not yet been shipped during the reporting period.
even so, sales of overseas products increased significantly year-on-year.
, especially in some countries, completed the certification of new plants, began to order in large quantities, increasing the first half of overseas business revenue.
the first half of 2020, Gan Li Pharmaceutical's main foreign business income (mainly including RAW export income, medical device export revenue) was 26.8346 million yuan, an increase of 279.85 percent over the same period.
.